Trials / Completed
CompletedNCT01949883
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Constellation Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
First in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPI-0610 |
Timeline
- Start date
- 2013-09-05
- Primary completion
- 2017-12-20
- Completion
- 2017-12-20
- First posted
- 2013-09-25
- Last updated
- 2024-05-08
Source: ClinicalTrials.gov record NCT01949883. Inclusion in this directory is not an endorsement.